These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3338011)

  • 1. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
    Kardinal CG; Perry MC; Korzun AH; Rice MA; Ginsberg S; Wood WC
    Cancer; 1988 Feb; 61(3):415-9. PubMed ID: 3338011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
    Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
    J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil compared to chemotherapy plus hormonal therapy with tamoxifen in the treatment of advanced breast cancer: an interim analysis.
    Perry MC; Kardinal CG; Weinberg V; Ginsberg SJ; Hughes A; Wood W
    J Steroid Biochem; 1985 Dec; 23(6B):1135-40. PubMed ID: 3912618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
    Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
    J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
    Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
    Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
    Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
    J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.
    Fisher B; Redmond C; Legault-Poisson S; Dimitrov NV; Brown AM; Wickerham DL; Wolmark N; Margolese RG; Bowman D; Glass AG
    J Clin Oncol; 1990 Jun; 8(6):1005-18. PubMed ID: 2189950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
    Falkson G; Gelman RS; Tormey DC; Falkson CI; Wolter JM; Cummings FJ
    J Clin Oncol; 1987 Jun; 5(6):881-9. PubMed ID: 3585444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
    Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
    Hortobagyi GN; Bodey GP; Buzdar AU; Frye D; Legha SS; Malik R; Smith TL; Blumenschein GR; Yap HY; Rodriguez V
    J Clin Oncol; 1987 Mar; 5(3):354-64. PubMed ID: 3819804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of adjuvant chemotherapy in male breast cancer.
    Patel HZ; Buzdar AU; Hortobagyi GN
    Cancer; 1989 Oct; 64(8):1583-5. PubMed ID: 2676137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
    J Clin Oncol; 1988 Apr; 6(4):679-88. PubMed ID: 2895801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.
    Ahmann FR; Jones SE; Moon TE
    J Surg Oncol; 1988 Feb; 37(2):116-22. PubMed ID: 3343839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
    Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
    J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.
    Kardinal CG; Perry MC; Weinberg V; Wood W; Ginsberg S; Raju RN
    Breast Cancer Res Treat; 1983; 3(4):365-71. PubMed ID: 6365209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial.
    Viladiu P; Alonso MC; Avella A; Beltrán M; Borrás J; Ojeda B; Bosch FX
    Cancer; 1985 Dec; 56(12):2745-50. PubMed ID: 3902200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.
    Levine MN; Gent M; Hryniuk WM; Bramwell V; Abu-Zahra H; DePauw S; Arnold A; Findlay B; Levin L; Skillings J
    J Clin Oncol; 1990 Jul; 8(7):1217-25. PubMed ID: 2193119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
    Morris DM; Elias EG; Didolkar MS; Brown SD
    J Surg Oncol; 1985 Jul; 29(3):154-7. PubMed ID: 3001423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.